MeiraGTx Holdings plc (MGTX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

MeiraGTx Holdings plc (MGTX) Healthcare & Pipeline Overview

MeiraGTx Holdings plc is a clinical-stage gene therapy company focused on developing treatments for serious diseases, including ocular, degenerative, and neurodegenerative conditions. With a focus on gene therapy, MeiraGTx is positioned to address unmet needs in areas like inherited blindness, Parkinson's, and ALS, supported by collaborations like the one with Janssen Pharmaceuticals.

What Is the Investment Thesis for MGTX?

The company's focus on ocular, degenerative, and neurodegenerative diseases offers substantial market opportunities. Key value drivers include the advancement of its clinical programs, particularly the Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, and RPE65-deficiency, with potential data readouts serving as catalysts. The collaboration with Janssen Pharmaceuticals for regulatable gene therapy using riboswitch technology adds another layer of potential value. However, the company's negative profit margin of -140.3% underscores the risks associated with clinical-stage biotech companies, including clinical trial failures and regulatory hurdles. Successful commercialization of its therapies is crucial for long-term value creation.

Based on FMP financials and quantitative analysis

MGTX Key Highlights

Market capitalization of $1.19B reflects investor confidence in MeiraGTx's gene therapy platform and pipeline.

• Gross margin of 94.0% indicates strong potential profitability upon successful commercialization of its therapies.
• Clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, and RPE65-deficiency represent near-term catalysts.
• Research collaboration with Janssen Pharmaceuticals provides validation of MeiraGTx's technology and potential for future revenue streams.
• Focus on ocular, degenerative, and neurodegenerative diseases addresses significant unmet medical needs.

Who Are MGTX's Competitors?

MGTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MGTX's Key Strengths?

Proprietary gene therapy platform

• Diversified pipeline of clinical and preclinical programs
• Strategic collaboration with Janssen Pharmaceuticals
• Focus on high-unmet-need diseases

What Are MGTX's Weaknesses?

Clinical-stage company with no approved products

• Negative profit margin
• Reliance on clinical trial success
• High R&D expenses

What Could Drive MGTX Stock Higher?

Data readouts from Phase 1/2 clinical trials for Achromatopsia, X-Linked Retinitis Pigmentosa, and RPE65-deficiency.

• Progression of clinical programs in radiation-induced Xerostomia and Parkinson's disease.
• Potential for new strategic collaborations and partnerships.
• Regulatory submissions and approvals for its gene therapy programs.

What Are the Key Risks for MGTX?

Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.

• Clinical trial failures could delay or halt the development of its therapies.
• Regulatory hurdles could delay or prevent the approval of its gene therapy programs.
• Competition from other gene therapy companies could limit its market share.
• Reimbursement challenges could limit access to its therapies.
• High R&D expenses could strain its financial resources.

What Are the Growth Opportunities for MGTX?

• Expansion into New Therapeutic Areas: MeiraGTx has the opportunity to leverage its gene therapy platform to expand into new therapeutic areas beyond its current focus on ocular, degenerative, and neurodegenerative diseases. This could include targeting other genetic disorders or exploring gene therapy applications in oncology or infectious diseases. The market for gene therapies is projected to reach $25 billion by 2030, providing a significant growth runway for companies with innovative platforms and diversified pipelines. This expansion could be realized within the next 3-5 years.
• Advancement of Clinical Programs: The successful advancement of MeiraGTx's clinical programs, particularly its Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, and RPE65-deficiency, represents a significant growth opportunity. Positive clinical data could lead to regulatory approvals and commercialization, generating substantial revenue streams. Each of these indications addresses a significant unmet medical need, with potential market sizes ranging from $500 million to $1 billion per indication. This growth is contingent on clinical trial success and regulatory approvals, with timelines varying depending on the specific program.
• Strategic Collaborations and Partnerships: MeiraGTx can further accelerate its growth through strategic collaborations and partnerships with other pharmaceutical companies or research institutions. These collaborations can provide access to new technologies, funding, and expertise, enabling MeiraGTx to expand its pipeline and accelerate the development of its therapies. The collaboration with Janssen Pharmaceuticals is a prime example of this strategy, and further partnerships could unlock additional value. The timeline for securing new collaborations is uncertain but could materialize within the next 1-3 years.
• Commercialization of Approved Therapies: Upon successful regulatory approval of its therapies, MeiraGTx has the opportunity to generate significant revenue through commercialization. This includes establishing a sales and marketing infrastructure, securing reimbursement from payers, and effectively reaching patients in need. The commercial success of its therapies will depend on factors such as market access, pricing, and competitive landscape. The timeline for commercialization is dependent on regulatory approvals, with potential revenue generation starting within 1-2 years of approval.
• Expansion into New Geographic Markets: MeiraGTx can expand its geographic reach by entering new markets outside of its current focus. This could include expanding into Europe, Asia, or other regions with significant unmet medical needs. The global market for gene therapies is growing rapidly, and expanding into new geographic markets could provide MeiraGTx with access to a larger patient population and increased revenue potential. This expansion could be realized within the next 3-5 years.

What Are MGTX's Competitive Advantages?

• Proprietary Gene Therapy Platform: MeiraGTx's proprietary gene therapy platform provides a competitive advantage in developing targeted therapies for genetic diseases.
• Diversified Pipeline: The company's diversified pipeline of clinical and preclinical programs reduces risk and provides multiple opportunities for growth.
• Strategic Collaborations: Collaborations with pharmaceutical companies like Janssen Pharmaceuticals provide access to funding, expertise, and commercialization capabilities.
• Focus on High-Unmet-Need Diseases: MeiraGTx's focus on ocular, degenerative, and neurodegenerative diseases addresses significant unmet medical needs, providing a strong market opportunity.

What Does MGTX Do?

MeiraGTx Holdings plc, incorporated in 2015 and based in New York City, is a clinical-stage gene therapy company dedicated to developing innovative treatments for patients suffering from serious diseases. The company's primary focus is on gene therapy solutions for a range of conditions, including ocular diseases such as inherited blindness (Achromatopsia, X-Linked Retinitis Pigmentosa, and RPE65-deficiency), degenerative diseases, neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and Parkinson's disease, and Xerostomia following radiation treatment for head and neck cancers. MeiraGTx's approach involves leveraging its proprietary gene therapy platform to design and develop targeted therapies aimed at addressing the underlying genetic causes of these diseases. The company's clinical development programs include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's disease. In addition to its clinical programs, MeiraGTx is also focused on initiating a clinical program in xerostomia related to Sjogren's syndrome and has preclinical programs in neurodegenerative diseases. A key aspect of MeiraGTx's strategy involves strategic collaborations, such as its research collaboration agreement with Janssen Pharmaceuticals, Inc., to develop regulatable gene therapy treatments using the company's proprietary riboswitch technology. This collaboration enhances MeiraGTx's capabilities and expands its potential to develop innovative gene therapies for a wider range of diseases.

What Products and Services Does MGTX Offer?

• Develops gene therapies for ocular diseases, including inherited blindness.
• Creates treatments for Xerostomia following radiation treatment for head and neck cancers.
• Focuses on therapies for degenerative diseases.
• Develops treatments for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and Parkinson's disease.
• Conducts Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia.
• Initiates clinical programs in xerostomia related to Sjogren's syndrome.
• Engages in preclinical programs in neurodegenerative diseases.
• Collaborates with Janssen Pharmaceuticals to develop regulatable gene therapy treatments.

How Does MGTX Make Money?

• Develops proprietary gene therapy technologies and platforms.
• Conducts clinical trials to evaluate the safety and efficacy of its therapies.
• Seeks regulatory approvals from agencies like the FDA and EMA.
• Commercializes approved therapies through sales and marketing efforts.
• Collaborates with pharmaceutical companies to develop and commercialize gene therapies.

What Industry Does MGTX Operate In?

MeiraGTx operates within the rapidly evolving biotechnology industry, specifically in the gene therapy sector. The gene therapy market is experiencing significant growth, driven by advancements in gene editing technologies and increasing success rates in clinical trials. The competitive landscape includes both established pharmaceutical companies and emerging biotech firms focused on gene therapy. MeiraGTx differentiates itself through its proprietary gene therapy platform, diversified pipeline, and strategic collaborations. The company's focus on specific disease areas, such as inherited blindness and neurodegenerative diseases, allows it to target niche markets with high unmet needs.

Who Are MGTX's Key Customers?

• Patients suffering from ocular diseases, including inherited blindness.
• Patients with Xerostomia following radiation treatment for head and neck cancers.
• Patients with degenerative diseases.
• Patients with neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and Parkinson's disease.
• Pharmaceutical companies through research collaborations and licensing agreements.

Company Profile

MeiraGTx Holdings plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Alexandria Forbes. MGTX has traded publicly since 2018.

Return on equity for MeiraGTx Holdings plc stands at 474.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -49.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.55 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -11.3%, the inverse of the P/E and a quick read on earnings relative to price.

MGTX Valuation & Market Position

With a $1.19B market cap, MeiraGTx Holdings plc sits in the small-cap segment of the market. Analyst price targets span from $26.00 to $26.00, with a consensus of $26.00. At the current price of $12.85, that implies approximately 102% upside potential. Relative to its peer group, MGTX's quantitative score of 70/100 is roughly in line with the peer average of 79/100.

Quarterly Financial Performance: MeiraGTx Holdings plc

Revenue for MeiraGTx Holdings plc came in at $321.4M during Q2 FY2026, a 109604.4% improvement versus the preceding quarter. The company recorded net income of $160.7M, with diluted EPS of $1.71. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, MGTX averaged $0.18 in diluted EPS.

MeiraGTx Holdings plc's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 5.17 places it in the safe zone, indicating low near-term bankruptcy risk.

MeiraGTx Holdings plc has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 62.8% above estimates on average.

Over the past six months, MeiraGTx Holdings plc insiders filed 26 SEC Form 4 transactions — 8 sales and 18 purchases. On net that is roughly 3.7M shares acquired (about $3.1M) — insiders putting money in tends to read as conviction.

MGTX Financials

MGTX Latest News

MGTX Analyst Consensus

MGTX MoonshotScore

Common Questions About MGTX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources